11	72	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'enablement', 'direction':'RightToLeft', 'children':[{'start':(0, 0), 'end':(0, 8), 'text':'To identify kinases capable of circumventing RAF inhibition ,'}, {'label':'joint', 'direction':'None', 'children':[{'start':(0, 9), 'end':(0, 10), 'text':'we assembled'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(0, 11), 'end':(0, 19), 'text':'and stably expressed 597 sequence validated kinase ORF clones'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(0, 20), 'end':(0, 52), 'text':'representing ~ 75 % of annotated kinases ( Center for Cancer Systems Biology ( CCSB ) / Broad Institute Kinase ORF Collection ) in A375 , a B-RAF V600E malignant melanoma cell line'}, {'start':(0, 53), 'end':(0, 62), 'text':'that is sensitive to the RAF kinase inhibitor PLX4720 .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(1, 0), 'end':(1, 2), 'text':'ORF expressing cells'}, {'label':'joint', 'direction':'None', 'children':[{'start':(1, 3), 'end':(1, 15), 'text':'treated with 1 microM PLX4720 were screened for viability relative to untreated cells'}, {'start':(1, 16), 'end':(1, 35), 'text':'and normalized to an assay specific positive control , MEK1 S218 and 222D ( MEK1 DD ) ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 0), 'end':(2, 5), 'text':'Nine ORFs conferred resistance at levels'}, {'label':'joint', 'direction':'None', 'children':[{'start':(2, 6), 'end':(2, 12), 'text':'exceeding two standard deviations from the mean'}, {'start':(2, 13), 'end':(2, 21), 'text':'and were selected for follow-up analysis ( ) .'}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 0), 'end':(3, 9), 'text':'Three of nine candidate ORFs were receptor tyrosine kinases ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 10), 'end':(3, 17), 'text':'underscoring the potential of this class of kinases'}, {'start':(3, 18), 'end':(3, 22), 'text':'to engage resistance pathways .'}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(4, 0), 'end':(4, 3), 'text':'Resistance effects were validated'}, {'start':(4, 4), 'end':(4, 22), 'text':'and prioritized across a multi-point PLX4720 drug concentration scale in the B-RAF V600E cell lines A375 and SKMEL28 .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(5, 0), 'end':(5, 7), 'text':'The Ser and Thr MAP kinase kinase kinases'}, {'start':(5, 8), 'end':(5, 30), 'text':'( MAP3Ks ) MAP3K8 ( COT and Tpl2 ) and RAF1 ( C-RAF ) emerged as top candidates from both cell lines ;'}]}, {'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(5, 31), 'end':(5, 40), 'text':'these ORFs shifted the PLX4720 GI 50 by 10-600 fold'}, {'start':(5, 41), 'end':(5, 46), 'text':'without affecting viability ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(6, 0), 'end':(6, 21), 'text':'Both COT and C-RAF reduced sensitivity to PLX4720 in multiple B-RAF V600E cell lines ( ) confirming the ability of these kinases'}, {'start':(6, 22), 'end':(6, 28), 'text':'to mediate resistance to RAF inhibition .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(7, 0), 'end':(7, 3), 'text':'Next , we tested'}, {'start':(7, 4), 'end':(7, 16), 'text':'whether overexpression of these genes was sufficient to activate the MAPK pathway .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 0), 'end':(8, 22), 'text':'At baseline , COT expression increased ERK phosphorylation in a manner comparable to MEK1 DD , consistent with MAP kinase pathway activation .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'LeftToRight', 'children':[{'start':(9, 0), 'end':(9, 19), 'text':'Overexpression of wild-type COT or C-RAF resulted in constitutive phosphorylation of ERK and MEK in the presence of PLX4720 ,'}, {'start':(9, 20), 'end':(9, 26), 'text':'whereas kinase-dead derivatives had no effect .'}]}, {'label':'background', 'direction':'RightToLeft', 'children':[{'start':(10, 0), 'end':(10, 4), 'text':'Based on these results ,'}, {'start':(10, 5), 'end':(10, 22), 'text':'we hypothesized that COT and C-RAF drive resistance to RAF inhibition predominantly through re-activation of MAPK signaling .'}]}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 0), 'end':(11, 24), 'text':'Notably , of the nine candidate ORFs from our initial screen , a subset ( 3 ) did not show persistent ERK and MEK phosphorylation'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 25), 'end':(11, 28), 'text':'following RAF inhibition ,'}, {'start':(11, 29), 'end':(11, 39), 'text':'suggesting MAPK pathway independent alteration of drug sensitivity ( ) .'}]}]}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(12, 0), 'end':(12, 3), 'text':'Several groups have shown'}, {'start':(12, 4), 'end':(12, 22), 'text':'that C-RAF activation and heterodimerization with B-RAF constitute critical components of the cellular response to B-RAF inhibition - .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'contrast', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'contrast', 'direction':'None', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'start':(13, 0), 'end':(13, 6), 'text':'In A375 cells , endogenous C-RAF :'}, {'label':'background', 'direction':'LeftToRight', 'children':[{'start':(13, 7), 'end':(13, 12), 'text':'B-RAF heterodimers were measurable and inducible'}, {'start':(13, 13), 'end':(13, 19), 'text':'following treatment with PLX4720 ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(14, 0), 'end':(14, 6), 'text':'However , endogenous C-RAF phosphorylation at S338'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(14, 7), 'end':(14, 9), 'text':'-- an event'}, {'start':(14, 10), 'end':(14, 14), 'text':'required for C-RAF activation --'}]}]}, {'start':(14, 15), 'end':(14, 19), 'text':'remained low ( ) .'}]}, {'label':'background', 'direction':'RightToLeft', 'children':[{'start':(15, 0), 'end':(15, 11), 'text':'In contrast , ectopically expressed C-RAF was phosphorylated on S338 ( )'}, {'start':(15, 12), 'end':(15, 25), 'text':'and its PLX4720 resistance phenotype was associated with sustained MEK and ERK activation .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(16, 0), 'end':(16, 44), 'text':'Moreover , ectopic expression of a high activity C-RAF truncation mutant ( C-RAF ( W22 ) was more effective than wild-type C-RAF in mediating PLX4720 resistance and ERK activation ( ) , further indicating that elevated C-RAF activity may direct resistance to this agent .'}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(17, 0), 'end':(17, 16), 'text':'Consistent with this model , oncogenic alleles of NRAS and KRAS conferred PLX4720 resistance in A375 cells'}, {'start':(17, 17), 'end':(17, 18), 'text':'( )'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(17, 19), 'end':(17, 22), 'text':'and yielded sustained C-RAF'}, {'start':(17, 23), 'end':(17, 37), 'text':'( S338 ) and ERK phosphorylation in the context of drug treatment ( ) .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'start':(18, 0), 'end':(18, 1), 'text':'Thus ,'}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(18, 2), 'end':(18, 4), 'text':'although genetic alterations'}, {'start':(18, 5), 'end':(18, 8), 'text':'that engender C-RAF activation'}]}, {'label':'condition', 'direction':'RightToLeft', 'children':[{'start':(18, 9), 'end':(18, 29), 'text':'( e.g. , oncogenic RAS mutations ) tend to show mutual exclusivity with B-RAF V600E mutation , such co-occurring events ,'}, {'start':(18, 30), 'end':(18, 42), 'text':'might be favored in the context of acquired resistance to B-RAF inhibition .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'LeftToRight', 'children':[{'start':(19, 0), 'end':(19, 8), 'text':'To investigate the role of COT in melanoma ,'}, {'start':(19, 9), 'end':(19, 17), 'text':'we first determined its expression in human melanocytes .'}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(20, 0), 'end':(20, 1), 'text':'We found'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(20, 2), 'end':(20, 14), 'text':'that primary immortalized melanocytes ( B-RAF wild-type ) expressed COT ( ) ,'}, {'label':'joint', 'direction':'None', 'children':[{'start':(20, 15), 'end':(20, 25), 'text':'although ectopic B-RAF V600E expression reduced COT mRNA levels ( )'}, {'start':(20, 26), 'end':(20, 33), 'text':'and rendered COT protein undetectable ( ) .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'start':(21, 0), 'end':(21, 1), 'text':'Conversely ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(21, 2), 'end':(21, 29), 'text':'whereas ectopically expressed COT was only weakly detectable in A375 cells ( ) , shRNA mediated depletion of endogenous B-RAF V600E caused an increase in COT protein levels'}, {'start':(21, 30), 'end':(21, 40), 'text':'that correlated with the extent of B-RAF knockdown ( ) .'}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'start':(22, 0), 'end':(22, 4), 'text':'Moreover , treatment of COT'}, {'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(22, 5), 'end':(22, 20), 'text':'expressing A375 cells with PLX4720 led to a dose dependent increase in COT protein ( )'}, {'start':(22, 21), 'end':(22, 29), 'text':'without affecting ectopic COT mRNA levels ( ) .'}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(23, 0), 'end':(23, 13), 'text':'Thus , oncogenic B-RAF may antagonize COT expression largely through altered protein stability ,'}, {'start':(23, 14), 'end':(23, 30), 'text':'and B-RAF inhibition may potentiate the outgrowth of COT expressing cells during the course of treatment .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(24, 0), 'end':(24, 28), 'text':'Notably , neither C-RAF nor B-RAF alone or in combination was required for ERK phosphorylation in the context of COT expression , even in the presence of PLX4720 ,'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(24, 29), 'end':(24, 29), 'text':'suggesting'}, {'start':(24, 30), 'end':(24, 46), 'text':'that COT expression is sufficient to induce MAP kinase pathway activation in a RAF independent manner .'}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(25, 0), 'end':(25, 1), 'text':'We predicted'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(25, 2), 'end':(25, 4), 'text':'that cell lines'}, {'start':(25, 5), 'end':(25, 21), 'text':'expressing elevated COT in a B-RAF V600E background should exhibit de novo resistance to PLX4720 treatment .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'enablement', 'direction':'RightToLeft', 'children':[{'start':(26, 0), 'end':(26, 4), 'text':'To identify such instances ,'}, {'start':(26, 5), 'end':(26, 27), 'text':'we screened a panel of cell lines for evidence of MAP3K8 and COT copy number gains coincident with the B-RAF V600E mutation .'}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(27, 0), 'end':(27, 3), 'text':'Of 534 cell lines'}, {'start':(27, 4), 'end':(27, 13), 'text':'that had undergone copy number analysis and mutation profiling ,'}]}, {'start':(27, 14), 'end':(27, 26), 'text':'38 cell lines ( 7.1 % ) contained the B-RAF V600E mutation .'}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(28, 0), 'end':(28, 6), 'text':'Within this subgroup , two cell lines'}, {'start':(28, 7), 'end':(28, 18), 'text':'-- OUMS-23 ( colon cancer ) and RPMI-7951 ( melanoma ) --'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(28, 19), 'end':(28, 25), 'text':'also showed evidence of chromosomal copy gains'}, {'start':(28, 26), 'end':(28, 37), 'text':'spanning the MAP3K8 and COT locus and robust COT protein expression .'}]}]}, {'start':(29, 0), 'end':(29, 13), 'text':'We also screened a panel of melanoma short-term cultures for COT protein expression .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(30, 0), 'end':(30, 7), 'text':'Only one of these lines expressed COT :'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(30, 8), 'end':(30, 12), 'text':'M307 , a short-term culture'}, {'start':(30, 13), 'end':(30, 18), 'text':'derived from a B-RAF V600E tumor'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(30, 19), 'end':(30, 25), 'text':'that developed resistance to allosteric MEK inhibition'}, {'start':(30, 26), 'end':(30, 32), 'text':'following initial disease stabilization ( ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(31, 0), 'end':(31, 9), 'text':'All three cell lines were refractory to PLX4720 treatment ,'}, {'start':(31, 10), 'end':(31, 35), 'text':'exhibiting GI 50 values in the range of 8-10 microM ( ) and showing sustained ERK phosphorylation in the context of B-RAF inhibition ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(32, 0), 'end':(32, 9), 'text':'OUMS-23 and RPMI-7951 are MAPK pathway inhibitor-naive cell lines ,'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(32, 10), 'end':(32, 10), 'text':'implying'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(32, 11), 'end':(32, 23), 'text':'that COT may confer de novo resistance to RAF inhibition ( a phenomenon'}, {'start':(32, 24), 'end':(32, 34), 'text':'observed in ~ 10 % of B-RAF V600E melanomas ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(33, 0), 'end':(33, 16), 'text':'Next , we examined COT expression in the context of resistance to the clinical RAF inhibitor PLX4032'}, {'start':(33, 17), 'end':(33, 30), 'text':'by obtaining biopsy material from 3 patients with metastatic , B-RAF V600E melanoma .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(34, 0), 'end':(34, 9), 'text':'Each case consisted of frozen , lesion matched biopsy material'}, {'start':(34, 10), 'end':(34, 27), 'text':'obtained prior to and during treatment ( " pre-treatment " and " on-treatment " ; , ) ;'}]}, {'start':(34, 28), 'end':(34, 49), 'text':'additionally , one sample contained two independent biopsy specimens from the same relapsing tumor site ( " post-relapse " ; ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(35, 0), 'end':(35, 4), 'text':'Consistent with the experimental models'}, {'start':(35, 5), 'end':(35, 10), 'text':'presented above , quantitative real-time RT-PCR'}]}, {'start':(35, 11), 'end':(35, 15), 'text':'( qRT and PCR )'}]}, {'start':(35, 16), 'end':(35, 31), 'text':'analysis revealed increased COT mRNA expression concurrent with PLX4032 treatment in 2 of 3 cases .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'LeftToRight', 'children':[{'start':(36, 0), 'end':(36, 18), 'text':'COT mRNA levels were further increased in a relapsing specimen relative to its pre-treatment and on-treatment counterparts ( ,'}, {'start':(36, 19), 'end':(36, 23), 'text':'Patient # 1 ) .'}]}, {'label':'attribution', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(37, 0), 'end':(37, 15), 'text':'An additional , unmatched relapsed malignant melanoma biopsy showed elevated COT mRNA expression comparable to levels'}, {'start':(37, 16), 'end':(37, 21), 'text':'observed in RAF inhibitor resistant ,'}]}, {'start':(37, 22), 'end':(37, 28), 'text':'COT amplified cell lines ( ) .'}]}]}, {'start':(38, 0), 'end':(38, 29), 'text':'This specimen also exhibited robust MAPK pathway activation and elevated expression of B-RAF , C-RAF and COT relative to matched normal skin or B-RAF V600E cell lines ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(39, 0), 'end':(39, 16), 'text':'Sequencing studies of this tumor revealed no additional mutations in BRAF , NRAS or KRAS ( data'}, {'start':(39, 17), 'end':(39, 20), 'text':'not shown ) .'}]}]}]}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(40, 0), 'end':(40, 4), 'text':'These analyses provided clinical evidence'}, {'start':(40, 5), 'end':(40, 20), 'text':'that COT dependent mechanisms may be operant in at least some PLX4032 resistant malignant melanomas .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'enablement', 'direction':'RightToLeft', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(41, 0), 'end':(41, 14), 'text':'To determine if COT might actively regulate MEK and ERK phosphorylation in B-RAF V600E cells'}, {'start':(41, 15), 'end':(41, 21), 'text':'that harbor naturally elevated COT expression ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(41, 22), 'end':(41, 25), 'text':'we introduced shRNA constructs'}, {'start':(41, 26), 'end':(41, 31), 'text':'targeting COT into RPMI-7951 cells .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(42, 0), 'end':(42, 7), 'text':'Depletion of COT suppressed RPMI-7951 viability ( )'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(42, 8), 'end':(42, 14), 'text':'and decreased ERK phosphorylation ( ) ,'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(42, 15), 'end':(42, 15), 'text':'implying'}, {'start':(42, 16), 'end':(42, 35), 'text':'that targeting COT kinase activity might suppress MEK and ERK phosphorylation in cancer cells with COT overexpression or amplification .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(43, 0), 'end':(43, 21), 'text':'Treatment of RPMI-7951 cells with a small molecule COT kinase inhibitor- resulted in dose dependent suppression of MEK and ERK phosphorylation ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(43, 22), 'end':(43, 24), 'text':'providing additional evidence'}, {'start':(43, 25), 'end':(43, 38), 'text':'that COT contributes to MEK and ERK activation in these cells ( ) .'}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(44, 0), 'end':(44, 2), 'text':'We then considered'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(44, 3), 'end':(44, 4), 'text':'whether COT'}, {'start':(44, 5), 'end':(44, 22), 'text':'expressing cancer cells remain sensitive to MAPK pathway inhibition at a target downstream of COT or RAF .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(45, 0), 'end':(45, 19), 'text':'Here , we queried the OUMS-23 and RPMI-7951 cell lines for sensitivity to the MEK1 and 2 inhibitor CI-1040 .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(46, 0), 'end':(46, 24), 'text':'Interestingly , both cell lines were refractory to MEK inhibition ( ) and displayed sustained ERK phosphorylation even at 1 microM CI-1040 ( ) .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(47, 0), 'end':(47, 19), 'text':'Ectopic COT expression in A375 and SKMEL28 cells also conferred decreased sensitivity to the MEK inhibitors CI-1040 and AZD6244 ,'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(47, 20), 'end':(47, 20), 'text':'suggesting'}, {'start':(47, 21), 'end':(47, 31), 'text':'that COT expression alone was sufficient to induce this phenotype .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(48, 0), 'end':(48, 2), 'text':'Similar to results'}, {'start':(48, 3), 'end':(48, 25), 'text':'observed with pharmacological MEK inhibitors , MEK1 and 2 knockdown only modestly suppressed COT mediated ERK phosphorylation in A375 cells ( ) .'}]}, {'label':'same-unit', 'direction':'None', 'children':[{'start':(49, 0), 'end':(49, 5), 'text':'In accordance with prior observations ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(49, 6), 'end':(49, 10), 'text':'these data raised the possibility'}, {'start':(49, 11), 'end':(49, 23), 'text':'that COT may activate ERK through MEK independent and MEK dependent mechanisms .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'enablement', 'direction':'RightToLeft', 'children':[{'start':(50, 0), 'end':(50, 5), 'text':'To test this hypothesis directly ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(50, 6), 'end':(50, 12), 'text':'we performed an in vitro kinase assay'}, {'start':(50, 13), 'end':(50, 18), 'text':'using recombinant COT and ERK1 .'}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(51, 0), 'end':(51, 15), 'text':'Indeed , recombinant COT induced pThr202 and Tyr204 phosphorylation of ERK1 in vitro ( ) suggesting'}, {'label':'same-unit', 'direction':'None', 'children':[{'start':(51, 16), 'end':(51, 20), 'text':'that in certain contexts ,'}, {'start':(51, 21), 'end':(51, 32), 'text':'COT expression may potentiate ERK activation in a MEK independent manner .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(52, 0), 'end':(52, 18), 'text':'In experimental models , the use of RAF and MEK inhibitors in combination can override resistance to single-agents .'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(53, 0), 'end':(53, 2), 'text':'We therefore reasoned'}, {'start':(53, 3), 'end':(53, 14), 'text':'that combined RAF and MEK inhibition might circumvent COT driven resistance .'}]}]}]}]}, {'start':(54, 0), 'end':(54, 41), 'text':'In the setting of ectopic COT expression , exposure to AZD6244 or CI-1040 in combination with PLX470 ( 1 microM each ) reduced cell growth and pERK expression more effectively than did single-agent PLX4720 , even at concentrations of 10 microM .'}]}]}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(55, 0), 'end':(55, 16), 'text':'These data underscore the importance of this pathway in B-RAF V600E tumor cells and support earlier findings'}, {'start':(55, 17), 'end':(55, 30), 'text':'that dual B-RAF and MEK inhibition may help circumvent resistance to RAF inhibitors .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(56, 0), 'end':(56, 24), 'text':'B RAF mutations are found in ~ 8 % of all cancers and at high frequencies in malignant melanoma , colon and thyroid cancers .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'contrast', 'direction':'None', 'children':[{'start':(57, 0), 'end':(57, 13), 'text':'The clinical promise of selective RAF inhibitors has widespread ramifications for patient treatment ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(57, 14), 'end':(57, 16), 'text':'yet single agent'}, {'start':(57, 17), 'end':(57, 30), 'text':'targeted therapy is almost invariably followed by relapse due to acquired drug resistance .'}]}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(58, 0), 'end':(58, 2), 'text':'Our results suggest'}, {'start':(58, 3), 'end':(58, 6), 'text':'that ORF based ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(58, 7), 'end':(58, 20), 'text':'systematic functional screening may offer a powerful means to identify clinically relevant resistance mechanisms'}, {'start':(58, 21), 'end':(58, 27), 'text':'that also specify novel treatment strategies .'}]}]}]}, {'label':'contrast', 'direction':'None', 'children':[{'start':(59, 0), 'end':(59, 19), 'text':'In particular , resistance to RAF inhibition can be achieved by multiple MAP3K dependent mechanisms of MEK and ERK reactivation'}, {'start':(59, 20), 'end':(59, 44), 'text':'but might be intercepted through combined therapeutic modalities for MAPK pathway inhibition ( e.g. , RAF and MEK or RAF and COT combinations ) .'}]}]}]}]}]}]}, {'label':'cause', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(60, 0), 'end':(60, 11), 'text':'Future systematic drug resistance studies may be expanded to a genome scale'}, {'start':(60, 12), 'end':(60, 16), 'text':'that encompasses many compounds ,'}]}, {'start':(60, 17), 'end':(60, 33), 'text':'thereby enabling comprehensive identification of both therapy specific resistance genes and drug targets of novel therapeutics .'}]}]}
72	80	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(0, 0), 'end':(0, 1), 'text':'Methods summary'}, {'start':(1, 0), 'end':(1, 11), 'text':'The arrayed , lentiviral ORF screen was performed as previously described .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(2, 0), 'end':(2, 8), 'text':'Effects of individual ORFs on drug resistance were determined'}, {'start':(2, 9), 'end':(2, 22), 'text':'by measuring differential viability ( ratio of raw viability in 1 microM PLX4720 :'}]}, {'start':(2, 23), 'end':(2, 37), 'text':'control ) and subsequent normalization to an assay specific positive control , MEK1 DD .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 0), 'end':(3, 18), 'text':'Secondary screens were performed with the top nine candidate ORFs in 96-well format in A375 and SKMEL28 cells .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 0), 'end':(4, 22), 'text':'Prioritization was accomplished via generation of a GI 50 for each ORF across a multi-point PLX4720 concentration range in both cell lines .'}, {'start':(5, 0), 'end':(5, 19), 'text':'The effects of identified resistance ORFs on MAPK pathway activation were demonstrated using both biochemical and cell biological approaches .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'LeftToRight', 'children':[{'start':(6, 0), 'end':(6, 6), 'text':'Cell line copy number data was obtained'}, {'start':(6, 7), 'end':(6, 10), 'text':'as previously described .'}]}, {'start':(7, 0), 'end':(7, 11), 'text':'Detailed descriptions of all procedures are included in Materials and Methods .'}]}]}]}
0	1	{'start':(0, 0), 'end':(0, 12), 'text':'COT and MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation'}
175	176	{'start':(0, 0), 'end':(0, 1), 'text':'Supplementary Material'}
1	11	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(0, 0), 'end':(0, 17), 'text':'Oncogenic mutations in the serine and threonine kinase B-RAF are found in 50-70 % of malignant melanomas .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'contrast', 'direction':'RightToLeft', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(1, 0), 'end':(1, 3), 'text':'Pre-clinical studies have demonstrated'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(1, 4), 'end':(1, 27), 'text':'that the B-RAF V600E mutation predicts a dependency on the mitogen activated protein kinase ( MAPK ) signaling cascade in melanoma --- an observation'}, {'start':(1, 28), 'end':(1, 44), 'text':'that has been validated by the success of RAF and MEK inhibitors in clinical trials - .'}]}]}, {'start':(2, 0), 'end':(2, 18), 'text':'However , clinical responses to targeted anticancer therapeutics are frequently confounded by de novo or acquired resistance - .'}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 0), 'end':(3, 6), 'text':'Identification of resistance mechanisms in a manner'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 7), 'end':(3, 12), 'text':'that elucidates alternative \' druggable \''}, {'start':(3, 13), 'end':(3, 20), 'text':'targets may inform effective long-term treatment strategies .'}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 0), 'end':(4, 28), 'text':'Here , we expressed ~ 600 kinase and kinase related open reading frames ( ORFs ) in parallel to functionally interrogate resistance to a selective RAF kinase inhibitor .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'cause', 'direction':'LeftToRight', 'children':[{'start':(5, 0), 'end':(5, 7), 'text':'We identified MAP3K8 ( COT and TPL2 )'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(5, 8), 'end':(5, 12), 'text':'as a MAPK pathway agonist'}, {'start':(5, 13), 'end':(5, 24), 'text':'that drives resistance to RAF inhibition in B-RAF V600E cell lines .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 0), 'end':(6, 7), 'text':'COT activates ERK primarily through MEK dependent mechanisms'}, {'start':(6, 8), 'end':(6, 14), 'text':'that do not require RAF signaling .'}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(7, 0), 'end':(7, 15), 'text':'Moreover , COT expression is associated with de novo resistance in B-RAF V600E cultured cell lines'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(7, 16), 'end':(7, 23), 'text':'and acquired resistance in melanoma cells and tissue'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(7, 24), 'end':(7, 27), 'text':'obtained from relapsing patients'}, {'start':(7, 28), 'end':(7, 35), 'text':'following treatment with MEK or RAF inhibition .'}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 0), 'end':(8, 16), 'text':'We further identify combinatorial MAPK pathway inhibition or targeting of COT kinase activity as possible therapeutic strategies'}, {'start':(8, 17), 'end':(8, 25), 'text':'for reducing MAPK pathway activation in this setting .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 0), 'end':(9, 9), 'text':'Together , these results provide new insights into resistance mechanisms'}, {'label':'joint', 'direction':'None', 'children':[{'start':(9, 10), 'end':(9, 13), 'text':'involving the MAPK pathway'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 14), 'end':(9, 18), 'text':'and articulate an integrative approach'}, {'start':(9, 19), 'end':(9, 32), 'text':'through which high-throughput functional screens may inform the development of novel therapeutic strategies .'}]}]}]}]}
176	177	{'start':(0, 0), 'end':(0, 0), 'text':'1'}
177	178	{'start':(0, 0), 'end':(0, 0), 'text':'Figures'}
80	175	{'label':'topic-change', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(0, 0), 'end':(0, 2), 'text':'Materials and Methods'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(1, 0), 'end':(1, 7), 'text':'Center for Cancer Systems Biology ( CCSB )'}, {'start':(1, 8), 'end':(1, 15), 'text':'/ Broad Institute Kinase Open Reading Frame Collection'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 0), 'end':(2, 11), 'text':'We assembled a library of 597 kinase ORFs in pDONR-223 Entry vectors'}, {'start':(2, 12), 'end':(2, 15), 'text':'( Invitrogen ) .'}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 0), 'end':(3, 3), 'text':'Individual clones were end'}, {'start':(3, 4), 'end':(3, 12), 'text':'sequenced using vector specific primers in both directions .'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(4, 0), 'end':(4, 9), 'text':'Clones with substantial deviations from reported sequences were discarded .'}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(5, 0), 'end':(5, 7), 'text':'Entry clones and sequences are available via Addgene'}, {'start':(5, 8), 'end':(5, 11), 'text':'( www.addgene.org/human_kinases ) .'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(6, 0), 'end':(6, 7), 'text':'Kinase ORFs were assembled from multiple sources ;'}, {'label':'joint', 'direction':'None', 'children':[{'start':(6, 8), 'end':(6, 23), 'text':'337 kinases were isolated as single clones from the ORFeome 5.1 collection ( horfdb.dfci.harvard.edu ) ;'}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 24), 'end':(6, 42), 'text':'183 kinases were cloned from normal human tissue RNA ( Ambion ) by reverse transcription and subsequent PCR amplification'}, {'start':(6, 43), 'end':(6, 46), 'text':'to add Gateway sequences'}]}, {'start':(6, 47), 'end':(6, 50), 'text':'( Invitrogen ) ;'}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 51), 'end':(6, 56), 'text':'64 kinases were cloned from templates'}, {'start':(6, 57), 'end':(6, 63), 'text':'provided by the Harvard Institute of Proteomics'}]}, {'start':(6, 64), 'end':(6, 67), 'text':'( HIP ) ;'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 68), 'end':(6, 78), 'text':'and 13 kinases were cloned into the Gateway system from templates'}, {'start':(6, 79), 'end':(6, 83), 'text':'obtained from collaborating laboratories .'}]}]}]}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(7, 0), 'end':(7, 12), 'text':'The Gateway-compatible lentiviral vector pLX-Blast-V5 was created from the pLKO .1 backbone .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 0), 'end':(8, 14), 'text':'LR reactions were performed to introduce the 597 kinases into pLX-Blast-V5 according to manufacturers protocol'}, {'start':(8, 15), 'end':(8, 18), 'text':'( Invitrogen ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 0), 'end':(9, 3), 'text':'High throughout ORF screening'}, {'start':(10, 0), 'end':(10, 15), 'text':'A375 melanoma cells were plated in 384-well microtiter plates ( 500 cells per well ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 0), 'end':(11, 24), 'text':'The following day , cells were spin infected with the lentivirally packaged kinase ORF library in the presence of 8 ug and ml polybrene .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(12, 0), 'end':(12, 15), 'text':'48 hours post-infection , media was replaced with standard growth media ( 2 replicates ) ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(12, 16), 'end':(12, 16), 'text':'media'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(12, 17), 'end':(12, 20), 'text':'containing 1 microM PLX4720'}, {'start':(12, 21), 'end':(12, 24), 'text':'( 2 replicates ,'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(12, 25), 'end':(12, 30), 'text':'2 time points ) or media'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(12, 31), 'end':(12, 36), 'text':'containing 10 ug and ml blasticidin'}, {'start':(12, 37), 'end':(12, 41), 'text':'( 2 replicates ) .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'LeftToRight', 'children':[{'start':(13, 0), 'end':(13, 16), 'text':'After four days and 6 days , cell growth was assayed using Cell Titer-Glo ( Promega )'}, {'start':(13, 17), 'end':(13, 21), 'text':'according to manufacturer instructions .'}]}, {'start':(14, 0), 'end':(14, 6), 'text':'The entire experiment was performed twice .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(15, 0), 'end':(15, 4), 'text':'Identification of candidate resistance ORFs'}, {'start':(16, 0), 'end':(16, 8), 'text':'Raw luminescence values were imported into Microsoft Excel .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(17, 0), 'end':(17, 21), 'text':'Infection efficiency was determined by the percentage of duplicate averaged raw luminescence in blasticidin selected cells relative to non selected cells .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(18, 0), 'end':(18, 17), 'text':'ORFs with an infection efficiency of less than 0.70 were excluded from further analysis along with any ORF'}, {'start':(18, 18), 'end':(18, 30), 'text':'having a standard deviation of > 15,000 raw luminescence units between duplicates .'}]}, {'label':'enablement', 'direction':'RightToLeft', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(19, 0), 'end':(19, 2), 'text':'To identify ORFs'}, {'start':(19, 3), 'end':(19, 7), 'text':'whose expression affects proliferation ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(19, 8), 'end':(19, 26), 'text':'we compared the duplicate averaged raw luminescence of individual ORFs against the average and standard deviation of all control'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(19, 27), 'end':(19, 41), 'text':'treated cells via the z-score , or standard score , below , z = x-musigma'}, {'start':(19, 42), 'end':(19, 75), 'text':'where x = average raw luminescence of a given ORF , mu = the mean raw luminescence of all ORFs and sigma = the standard deviation of the raw luminescence of all wells .'}]}]}]}]}]}]}, {'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(20, 0), 'end':(20, 12), 'text':'Any individual ORF with a z-score > +2 or < -2 was annotated'}, {'label':'joint', 'direction':'None', 'children':[{'start':(20, 13), 'end':(20, 15), 'text':'as affecting proliferation'}, {'start':(20, 16), 'end':(20, 21), 'text':'and removed from final analysis .'}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(21, 0), 'end':(21, 6), 'text':'Differential proliferation was determined by the percentage'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(21, 7), 'end':(21, 14), 'text':'of duplicate averaged raw luminescence values in PLX4720'}, {'start':(21, 15), 'end':(21, 18), 'text':'( 1 microM )'}]}, {'start':(21, 19), 'end':(21, 25), 'text':'treated cells relative to untreated cells .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(22, 0), 'end':(22, 22), 'text':'Subsequently , differential proliferation was normalized to the positive control for PLX4720 resistance , MEK1 S218 and 222D ( MEK1 DD ) ,'}, {'start':(22, 23), 'end':(22, 30), 'text':'with MEK1 DD differential proliferation = 1.0 .'}]}, {'start':(23, 0), 'end':(23, 30), 'text':'MEK1 DD normalized differential proliferation for each individual ORF was averaged across two duplicate experiments , with two time points for each experiment ( day 4 and day 6 ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'LeftToRight', 'children':[{'start':(24, 0), 'end':(24, 5), 'text':'A z-score was then generated ,'}, {'start':(24, 6), 'end':(24, 17), 'text':'as described above , for average MEK1 DD normalized differential proliferation .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(25, 0), 'end':(25, 9), 'text':'ORFs with a z-score of > 2 were considered hits'}, {'start':(25, 10), 'end':(25, 18), 'text':'and were followed up in the secondary screen .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(26, 0), 'end':(26, 3), 'text':'ORF and shRNA expression'}, {'start':(27, 0), 'end':(27, 19), 'text':'ORFs were expressed from pLX-Blast-V5 ( lentiviral ) or pWZL-Blast , pBABE-Puro or pBABE-zeocin ( retroviral ) expression plasmids .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(28, 0), 'end':(28, 28), 'text':'For lentiviral transduction , 293T cells were transfected with 1 microg of pLX-Blast-V5-ORF or pLKO.1-shRNA , 900 ng Delta8 .9 ( gag , pol ) and 100 ng VSV-G'}, {'start':(28, 29), 'end':(28, 38), 'text':'using 6 microl Fugene6 transfection reagent ( Roche ) .'}]}]}]}, {'start':(29, 0), 'end':(29, 7), 'text':'Viral supernatant was harvested 72 h post-transfection .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(30, 0), 'end':(30, 22), 'text':'Mammalian cells were infected at a 1:10 -1:20 dilution of virus in 6-well plates in the presence of 5 microg and ml polybrene'}, {'start':(30, 23), 'end':(30, 46), 'text':'and centrifuged at 2250 RPM for 1 h at 37degrees C. Twenty-four hours after infection blasticidin ( pLX-Blast-V5 , 10 microg and ml )'}]}, {'start':(30, 47), 'end':(30, 59), 'text':'or puro ( pLKO .1 , 0.75 microg and ml ) was added'}]}, {'start':(30, 60), 'end':(30, 67), 'text':'and cells were selected for 48 hrs .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'LeftToRight', 'children':[{'start':(31, 0), 'end':(31, 21), 'text':'For retrovirus production , 293T were transfected with 1 microg of retroviral plasmid-ORF , 1 microg pCL-AMPHO and 100 ng VSV-G ,'}, {'start':(31, 22), 'end':(31, 25), 'text':'as described above .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(32, 0), 'end':(32, 4), 'text':'Cells were infected with retrovirus'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(32, 5), 'end':(32, 18), 'text':'containing supernatant at a 1:2 dilution in 5 microg and ml polybrene overnight ,'}, {'start':(32, 19), 'end':(32, 26), 'text':'followed by media change to growth medium .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(33, 0), 'end':(33, 9), 'text':'Infection was repeated once more ( twice total ) ,'}, {'start':(33, 10), 'end':(33, 15), 'text':'followed by selection , above .'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(34, 0), 'end':(34, 1), 'text':'Secondary Screen'}, {'label':'joint', 'direction':'None', 'children':[{'start':(35, 0), 'end':(35, 6), 'text':'A375 ( 1.5 x 10 3 )'}, {'label':'joint', 'direction':'None', 'children':[{'start':(35, 7), 'end':(35, 42), 'text':'and SKMEL28 cells ( 3 x 10 3 ) were seeded in 96-well plates for 18 h. ORF expressing lentivirus was added at a 1:10 dilution in the presence of 8 microg and ml polybrene ,'}, {'start':(35, 43), 'end':(35, 112), 'text':'and centrifuged at 2250 RPM and 37degrees C for 1 h. Following centrifugation , virus containing media was changed to normal growth media and allowed to incubate for 18 h. Twenty-four hours after infection , DMSO ( 1:1000 ) or 10x PLX4720 ( in DMSO ) was added to a final concentration of 100 , 10 , 1 , 0.1 , 0.01 , 0.001 , 0.0001 or 0.00001 microM .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(36, 0), 'end':(36, 9), 'text':'Cell viability was assayed using WST-1 ( Roche ) ,'}, {'start':(36, 10), 'end':(36, 21), 'text':'per manufacturer recommendation , 4 days after the addition of PLX4720 .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(37, 0), 'end':(37, 3), 'text':'Cell lines and reagents'}, {'start':(38, 0), 'end':(38, 50), 'text':'A375 , SKMEL28 , SKMEL30 , COLO-679 , WM451lu , SKMEL5 , Malme 3M , SKMEL30 , WM3627 , WM1976 , WM3163 , WM3130 , WM3629 , WM3453 , WM3682 and WM3702 were all grown in RPMI ( Cellgro ) , 10 % FBS and 1 % penicillin and streptomycin .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(39, 0), 'end':(39, 17), 'text':'M307 was grown in RPMI ( Cellgro ) , 10 % FBS and 1 % penicillin and streptomycin'}, {'start':(39, 18), 'end':(39, 24), 'text':'supplemented with 1 mM sodium pyruvate .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(40, 0), 'end':(40, 6), 'text':'293T and OUMS-23 were grown in DMEM'}, {'start':(40, 7), 'end':(40, 20), 'text':'( Cellgro ) , 10 % FBS and 1 % penicillin and streptomycin .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(41, 0), 'end':(41, 8), 'text':'RPMI-7951 cells ( ATCC ) were grown in MEM'}, {'start':(41, 9), 'end':(41, 22), 'text':'( Cellgro ) , 10 % FBS and 1 % penicillin and streptomycin .'}]}, {'start':(42, 0), 'end':(42, 22), 'text':'Wild-type primary melanocytes were grown in HAM \'s F10 ( Cellgro ) , 10 % FBS and 1 % penicillin and streptomycin .'}]}]}, {'start':(43, 0), 'end':(43, 55), 'text':'B-RAF V600E -expressing primary melanocytes were grown in TIVA media [ Ham \'s F-10 ( Cellgro ) , 7 % FBS , 1 % penicillin and streptomycin , 2mM glutamine ( Cellgro ) , 100 uM IBMX , 50 ng and ml TPA , 1mM dbcAMP ( Sigma ) and 1 microM sodium vanadate ] .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(44, 0), 'end':(44, 4), 'text':'CI-1040 ( PubChem ID :'}, {'start':(44, 5), 'end':(44, 20), 'text':'6918454 ) was purchased from Shanghai Lechen International Trading Co. , AZD6244 ( PubChem ID :'}]}, {'start':(44, 21), 'end':(44, 32), 'text':'10127622 ) from Selleck Chemicals , and PLX4720 ( PubChem ID :'}]}, {'start':(44, 33), 'end':(44, 37), 'text':'24180719 ) from Symansis .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(45, 0), 'end':(45, 4), 'text':'RAF265 ( PubChem ID :'}, {'label':'same-unit', 'direction':'None', 'children':[{'start':(45, 5), 'end':(45, 6), 'text':'11656518 )'}, {'start':(45, 7), 'end':(45, 15), 'text':'was a generous gift from Novartis Pharma AG .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'RightToLeft', 'children':[{'start':(46, 0), 'end':(46, 3), 'text':'Unless otherwise indicated ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(46, 4), 'end':(46, 10), 'text':'all drug treatments were for 16 h.'}, {'label':'joint', 'direction':'None', 'children':[{'start':(46, 11), 'end':(46, 14), 'text':'Activated alleles of NRAS'}, {'start':(46, 15), 'end':(46, 22), 'text':'and KRAS have been previously described , .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(47, 0), 'end':(47, 3), 'text':'Pharmacologic Growth Inhibition Assays'}, {'start':(48, 0), 'end':(48, 18), 'text':'Cultured cells were seeded into 96-well plates ( 3,000 cells per well ) for all melanoma cell lines ;'}]}]}, {'start':(48, 19), 'end':(48, 25), 'text':'1,500 cells were seeded for A375 .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(49, 0), 'end':(49, 18), 'text':'Twenty-four hours after seeding , serial dilutions of the relevant compound were prepared in DMSO added to cells ,'}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(49, 19), 'end':(49, 22), 'text':'yielding final drug concentrations'}, {'start':(49, 23), 'end':(49, 33), 'text':'ranging from 100 microM to 1 x 10 5 microM ,'}]}, {'start':(49, 34), 'end':(49, 44), 'text':'with the final volume of DMSO not exceeding 1 % .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(50, 0), 'end':(50, 5), 'text':'Cells were incubated for 96 h'}, {'start':(50, 6), 'end':(50, 10), 'text':'following addition of drug .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(51, 0), 'end':(51, 8), 'text':'Cell viability was measured using the WST1 viability assay'}, {'start':(51, 9), 'end':(51, 12), 'text':'( Roche ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(52, 0), 'end':(52, 7), 'text':'Viability was calculated as a percentage of control'}, {'start':(52, 8), 'end':(52, 15), 'text':'( untreated cells ) after background subtraction .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(53, 0), 'end':(53, 14), 'text':'A minimum of six replicates were performed for each cell line and drug combination .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(54, 0), 'end':(54, 17), 'text':'Data from growth-inhibition assays were modeled using a nonlinear regression curve fit with a sigmoid dose response .'}, {'label':'joint', 'direction':'None', 'children':[{'start':(55, 0), 'end':(55, 3), 'text':'These curves were displayed'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(55, 4), 'end':(55, 13), 'text':'and GI 50 generated using GraphPad Prism 5 for Windows'}, {'start':(55, 14), 'end':(55, 17), 'text':'( GraphPad ) .'}]}]}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(56, 0), 'end':(56, 2), 'text':'Sigmoid response curves'}, {'start':(56, 3), 'end':(56, 24), 'text':'that crossed the 50 % inhibition point at or above 10 microM have GI 50 values annotated as > 10 microM .'}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(57, 0), 'end':(57, 9), 'text':'For single-dose studies , the identical protocol was followed ,'}, {'start':(57, 10), 'end':(57, 24), 'text':'using a single dose of indicated drug ( 1 microM unless otherwise noted ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(58, 0), 'end':(58, 2), 'text':'Immunoblots and immunoprecipitations'}, {'label':'joint', 'direction':'None', 'children':[{'start':(59, 0), 'end':(59, 6), 'text':'Cells were washed twice with ice-cold PBS'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(59, 7), 'end':(59, 38), 'text':'and lysed with 1 % NP-40 buffer [ 150 mM NaCl , 50 mM Tris pH 7.5 , 2 mM EDTA pH 8 , 25 mM NaF and 1 % NP-40 ]'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(59, 39), 'end':(59, 42), 'text':'containing 2x protease inhibitors'}, {'start':(59, 43), 'end':(59, 57), 'text':'( Roche ) and 1x Phosphatase Inhibitor Cocktails I and II ( CalBioChem ) .'}]}]}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(60, 0), 'end':(60, 7), 'text':'Lysates were quantified ( Bradford assay ) ,'}, {'label':'joint', 'direction':'None', 'children':[{'start':(60, 8), 'end':(60, 16), 'text':'normalized , reduced , denatured ( 95 degreesC )'}, {'start':(60, 17), 'end':(60, 33), 'text':'and resolved by SDS gel electrophoresis on 10 % Tris and Glycine gels ( Invitrogen ) .'}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(61, 0), 'end':(61, 5), 'text':'Protein was transferred to PVDF membranes'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(61, 6), 'end':(61, 10), 'text':'and probed with primary antibodies'}, {'start':(61, 11), 'end':(61, 52), 'text':'recognizing pERK1 and 2 ( T202 and Y204 ) , pMEK1 and 2 ( S217 and 221 ) , MEK1 and 2 , MEK1 , MEK2 , C-RAF ( rabbit host ) , pC-RAF ( pS338 ) ( Cell Signaling Technology ;'}]}]}, {'start':(61, 53), 'end':(61, 59), 'text':'1:1,000 ) , V5-HRP ( Invitrogen ;'}]}, {'start':(61, 60), 'end':(61, 82), 'text':'( 1:5,000 ) , COT ( 1:500 ) , B-RAF ( 1:2,000 ) , Actin ( 1:1,000 ) , Actin-HRP ( 1:1,000 ;'}]}, {'start':(61, 83), 'end':(61, 92), 'text':'Santa Cruz ) ) , C-RAF ( mouse host ;'}]}, {'start':(61, 93), 'end':(61, 94), 'text':'1:1,000 ;'}]}, {'start':(61, 95), 'end':(61, 110), 'text':'BD Transduction Labs ) , Vinculin ( Sigma ; 1:20,000 ) , AXL ( 1:500 ;'}]}, {'start':(61, 111), 'end':(61, 114), 'text':'R&D Systems ) .'}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(62, 0), 'end':(62, 31), 'text':'After incubation with the appropriate secondary antibody ( anti-rabbit , anti-mouse IgG , HRP linked ; 1:1,000 dilution , Cell Signaling Technology or anti-goat IgG , HRP linked ; 1:1,000 dilution ;'}, {'start':(62, 32), 'end':(62, 35), 'text':'Santa Cruz ) ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(62, 36), 'end':(62, 40), 'text':'proteins were detected using chemiluminescence'}, {'start':(62, 41), 'end':(62, 44), 'text':'( Pierce ) .'}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'background', 'direction':'LeftToRight', 'children':[{'start':(63, 0), 'end':(63, 13), 'text':'Immunoprecipitations were performed overnight at 4degrees C in 1 % NP-40 lysis buffer ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(63, 14), 'end':(63, 30), 'text':'as described above , at a concentration of 1 microg and mul total protein using an antibody'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(63, 31), 'end':(63, 32), 'text':'recognizing C-RAF'}, {'start':(63, 33), 'end':(63, 40), 'text':'( 1:50 ; Cell Signaling Technology ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(64, 0), 'end':(64, 1), 'text':'Antibody :'}, {'start':(64, 2), 'end':(64, 23), 'text':'antigen complexes were bound to Protein A agarose ( 25 microL , 50 % slurry ; Pierce ) for 2 hrs .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'temporal', 'direction':'None', 'children':[{'start':(65, 0), 'end':(65, 12), 'text':'at 4degrees C. Beads were centrifuged and washed three times in lysis buffer'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(65, 13), 'end':(65, 25), 'text':'and eluted and denatured ( 95 degreesC ) in 2x reduced sample buffer'}, {'start':(65, 26), 'end':(65, 29), 'text':'( Invitrogen ) .'}]}]}, {'start':(66, 0), 'end':(66, 5), 'text':'Immunoblots were performed as above .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(67, 0), 'end':(67, 8), 'text':'Phospho protein quantification was performed using NIH Image J.'}, {'label':'comparison', 'direction':'LeftToRight', 'children':[{'start':(68, 0), 'end':(68, 60), 'text':'Lysates from tumor and matched normal skin were generated by mechanical homogenization of tissue in RIPA [ 50 mM Tris ( pH 7.4 ) , 150 mM NaCl , 1mM EDTA , 0.1 % SDS , 1.0 % NaDOC , 1.0 % Triton X-100 , 25 mM NaF , 1mM NA 3 VO 4 ] containing protease and phosphatase inhibitors ,'}, {'start':(68, 61), 'end':(68, 63), 'text':'as above .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(69, 0), 'end':(69, 8), 'text':'Subsequent normalization and immunoblots were performed as above .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(70, 0), 'end':(70, 3), 'text':'Biopsied melanoma tumor material'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(71, 0), 'end':(71, 8), 'text':'Biopsied tumor material consisted of discarded and de-identified tissue'}, {'label':'joint', 'direction':'None', 'children':[{'start':(71, 9), 'end':(71, 14), 'text':'that was obtained with informed consent'}, {'start':(71, 15), 'end':(71, 38), 'text':'and characterized under protocol 02-017 ( paired samples , Massachusetts General Hospital ) and 07-087 ( unpaired sample , Dana-Farber Cancer Institute ) .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(72, 0), 'end':(72, 19), 'text':'For paired specimens , \' on-treatment \' samples were collected 10-14 days after initiation of PLX4032 treatment ( ) .'}, {'label':'joint', 'direction':'None', 'children':[{'start':(73, 0), 'end':(73, 4), 'text':'Inhibition of COT kinase activity'}, {'label':'joint', 'direction':'None', 'children':[{'start':(74, 0), 'end':(74, 8), 'text':'Adherent RPMI-7951 cells were washed twice with 1x PBS'}, {'start':(74, 9), 'end':(74, 16), 'text':'and incubated overnight in serum-free growth media .'}]}]}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(75, 0), 'end':(75, 27), 'text':'Subsequently , 4 - ( 3-Chloro-4-fluorophenylamino ) -6 - ( pyridin-3-yl-methylamino ) -3 - cyano - [ 1,7 ] - naphthyridine ( EMD ; TPL2 inhibitor I ;'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(75, 28), 'end':(75, 30), 'text':'Cat # :'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(75, 31), 'end':(75, 35), 'text':'616373 , PubChem ID :'}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(75, 36), 'end':(75, 38), 'text':'9549300 ) ,'}, {'start':(75, 39), 'end':(75, 46), 'text':'suspended in DMSO at the indicated concentration ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(75, 47), 'end':(75, 54), 'text':'was added to cells for 1 hour ,'}, {'label':'background', 'direction':'LeftToRight', 'children':[{'start':(75, 55), 'end':(75, 60), 'text':'after which protein extracts were made'}, {'start':(75, 61), 'end':(75, 64), 'text':'as described above .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(76, 0), 'end':(76, 3), 'text':'Quantitative RT and PCR'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(77, 0), 'end':(77, 8), 'text':'mRNA was extracted from cell lines and fresh-frozen tumors'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(77, 9), 'end':(77, 12), 'text':'using the RNeasy kit'}, {'start':(77, 13), 'end':(77, 16), 'text':'( Qiagen ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(78, 0), 'end':(78, 7), 'text':'Total mRNA was used for subsequent reverse transcription'}, {'start':(78, 8), 'end':(78, 41), 'text':'using the SuperScript III First-Strand Synthesis SuperMix ( Invitrogen ) for cell lines and unpaired tumor samples , and the SuperScript VILO cDNA synthesis kit ( Invitrogen ) for paired frozen tumor samples .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'manner-means', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(79, 0), 'end':(79, 10), 'text':'5 microl of the RT reaction was used for quantitative PCR'}, {'start':(79, 11), 'end':(79, 24), 'text':'using SYBR Green PCR Master Mix and gene specific primers , in triplicate ,'}]}, {'start':(79, 25), 'end':(79, 33), 'text':'using an ABI 7300 Real Time PCR System .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(80, 0), 'end':(80, 7), 'text':'Primers used for detection are as follows ;'}, {'start':(80, 8), 'end':(80, 10), 'text':'COT forward :'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(80, 11), 'end':(80, 21), 'text':'5 \'- CAA GTG AAG AGC CAG CAGTTT -3 \' ;'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(80, 22), 'end':(80, 24), 'text':'COT reverse :'}, {'start':(80, 25), 'end':(80, 36), 'text':'5 \'- GCA AGC AAATCC TCC ACA GTT C -3 \' ;'}]}, {'start':(80, 37), 'end':(80, 39), 'text':'TBP forward :'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(80, 40), 'end':(80, 52), 'text':'5 \'- CCC GAA ACG CCG AAT ATA ATC C -3 \' ;'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(80, 53), 'end':(80, 55), 'text':'TBP reverse :'}, {'label':'joint', 'direction':'None', 'children':[{'start':(80, 56), 'end':(80, 68), 'text':'5 \'- GAC TGT TCT TCA CTC TTG GCT C -3 \' ;'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(80, 69), 'end':(80, 71), 'text':'GAPDH forward :'}, {'label':'joint', 'direction':'None', 'children':[{'start':(80, 72), 'end':(80, 83), 'text':'5 \'- CAT CAT CTC TGC CCC CTC T -3 \' ;'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(80, 84), 'end':(80, 86), 'text':'GAPDH reverse :'}, {'start':(80, 87), 'end':(80, 99), 'text':'5 \' - GGT GCT AAG CAG TTG GTG GT -3 \' .'}]}]}]}]}]}]}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(81, 0), 'end':(81, 3), 'text':'In vitro kinase assay'}, {'label':'background', 'direction':'LeftToRight', 'children':[{'start':(82, 0), 'end':(82, 5), 'text':'In vitro kinase assays were performed'}, {'start':(82, 6), 'end':(82, 29), 'text':'as previously described using 1 microg each of COT ( amino acids 30-397 , R&D Systems ) and inactive ERK1 ( Millipore ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(83, 0), 'end':(83, 2), 'text':'Cellular viability assays'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(84, 0), 'end':(84, 6), 'text':'Adherent RPMI-7951 cells were infected with virus'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(84, 7), 'end':(84, 12), 'text':'expressing shRNAs against COT or Luciferase'}, {'start':(84, 13), 'end':(84, 16), 'text':'as described above .'}]}]}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(85, 0), 'end':(85, 20), 'text':'Following selection , cells were plated ( 1.5 x10 5 cells and well ) onto a 24-well plate in quadruplicate .'}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(86, 0), 'end':(86, 7), 'text':'Viable cells were counted via trypan blue exclusion'}, {'start':(86, 8), 'end':(86, 19), 'text':'using a VI-CELL Cell Viability Analyzer , per manufacturer \'s specifications .'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(87, 0), 'end':(87, 4), 'text':'Quadruplicate cell counts were averaged'}, {'start':(87, 5), 'end':(87, 14), 'text':'and normalized relative to that of the control shRNA .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(88, 0), 'end':(88, 4), 'text':'The Cancer Cell line encyclopedia'}, {'start':(88, 5), 'end':(88, 7), 'text':'( CCLE )'}]}, {'label':'enablement', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(89, 0), 'end':(89, 34), 'text':'The Cancer Cell line encyclopedia ( CCLE ) project is a collaboration between the Broad Institute , the Novartis Institutes for Biomedical Research ( NIBR ) and the Genomics Institute of the Novartis Research Foundation'}, {'start':(89, 35), 'end':(89, 37), 'text':'( GNF )'}]}, {'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(89, 38), 'end':(89, 54), 'text':'to conduct a detailed genetic and pharmacologic characterization of a large panel of human cancer models ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(89, 55), 'end':(89, 59), 'text':'to develop integrated computational analyses'}, {'label':'joint', 'direction':'None', 'children':[{'start':(89, 60), 'end':(89, 67), 'text':'that link distinct pharmacologic vulnerabilities to genomic patterns'}, {'start':(89, 68), 'end':(89, 79), 'text':'and to translate cell line integrative genomics into cancer patient stratification .'}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(90, 0), 'end':(90, 5), 'text':'All OncoMap mutation data and SNP-array'}, {'start':(90, 6), 'end':(90, 15), 'text':'derived copy number data is available online at www.broadinstitute.org/ccle .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(91, 0), 'end':(91, 5), 'text':'Expression profiling of cancer cell lines'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(92, 0), 'end':(92, 5), 'text':'We carried out oligonucleotide microarray analysis'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(92, 6), 'end':(92, 16), 'text':'using the GeneChip Human Genome U133 Plus 2.0 Affymetrix expression array'}, {'start':(92, 17), 'end':(92, 25), 'text':'( Affymetrix , Santa Clara , CA ) .'}]}]}]}, {'start':(93, 0), 'end':(93, 19), 'text':'Samples were converted to labeled , fragmented , cRNA per the Affymetrix protocol for use on the expression microarray .'}]}]}]}]}]}]}]}]}, {'start':(94, 0), 'end':(94, 6), 'text':'shRNA constructs used ( pLKO .1 )'}]}]}]}
